Form 4: Alnylam Director David E.I. Pyott Acquires Stock Options

Director David E.I. Pyott acquired 5,228 stock options in Alnylam Pharmaceuticals on May 16, 2024, according to a Form 4 filing.

Summary

• David E.I. Pyott, a director of Alnylam Pharmaceuticals, acquired 5,228 stock options on May 16, 2024.
• The options have an exercise price of $151.22.
• These options vest in full on the earlier of the first anniversary of the grant date (May 16, 2025) or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the first anniversary of the grant date.
• The options expire on May 16, 2034.
• Following the transaction, Pyott directly owns 5,228 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment but suggests confidence.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment regarding the company's prospects.

Key Dates